



# SynVision Chem

INNOVATION EXCELLENCE

YOUR PARTNER FOR

Custom  
Synthesis

Process  
Development

Medicinal  
Chemistry

CRAM

---

📍 19/A, Punit Industries, D-1 Block MIDC Chinchwad, Pune: 411019

☎ +91 8530390457 / +91 9765800457

✉ [info@synvisionchem.com](mailto:info@synvisionchem.com)

🌐 <http://www.synvisionchem.com>



# SynVision Chem


INNOVATION EXCELLENCE

Custom  
Synthesis

- Tailor-made molecules from mg to multi-kg
- Design and synthesis of novel APIs and intermediates.
- Impurities and reference standards for regulatory submissions.
- Multi-step organic synthesis of challenging structures.


**Delivered over 100 projects in last three years  
with 85% Success Rate**

## Reference Compound




**Feruloyl putrescine**


## Agro-Chemicals




**Difenturon**




## API




**Acoramidis**



**Mesdopetam**



**Obefazimod**




**Mesdopetam**

## From lab route to robust, plant-ready process


- Route scouting and selection for a sustainable and economic process.
- Process optimization for yield, purity and cycle time
- Identification and control of critical process parameters.
- Development of robust, reproducible procedures

Smooth tech-transfer from lab to kilo/pilot scale


## API KSM and Intermediates developed on an exclusive basis




Suvorexant KSM




Chlorphthalidone KSM




Ziprasidone KSM



Apixaban KSM




Boc-Lys(Boc)-OH and DCHA Salt



Semaglutide KSM



## Tapinarof




Status: API / Intermediates / Impurities Available

Novel (patented) process available for licensing

Tapinarof is a first-in-class aryl hydrocarbon receptor (AhR) agonist, approved by the U.S. FDA in 2022 for the treatment of psoriasis and atopic dermatitis.

## Acoltremon




Novel Process

Status: API/Intermediates Available

Acoltremon is a TRPM8 agonist. approved by the U.S. FDA in 2025 for the treatment of Dry Eye Disease.

## Acoramidis



Status: API/Intermediates / Impurities Available

Acoramidis is an approved drug used for the treatment of transthyretin (TTR) amyloidosis.



**SynVision Chem**

INNOVATION EXCELLENCE

## Capabilities

### R&D LAB DESIGNED FOR CHALLENGING CHEMISTRY

- Fully equipped synthetic R&D lab dedicated to custom synthesis and process development.
- Set up to handle a wide range of organic reactions and multi-step syntheses.
- Infrastructure to support Inert atmosphere, temperature-controlled reactions and scalable process development.

### Analytical Support:


- HPLC-UV/PDA/CAD Systems
- GC, GC-HS, GC-Mass Spectrometry
- LC-MS & LC-MS/MS
- Preparative LC Systems
- Karl Fischer (KF) Titration

### Pilot and Manufacturing:

- Pilot-scale reactors up to 200 L for scale-up and process verification.
- Capability to handle custom synthesis from mg to multi-kg quantities.

From the first milligram to the final batch  
data-backed decisions at every step.

- End-to-end solution



## Value Creation for Your Business

- Enrich your product portfolio.
- Minimize R&D cost.
- Maximise the Success-to-Risk ratio for new product development.
- Use your facility at maximum capacity.
- Accelerate time-to-market.
- Reduce technical & supply risk with robust, documented routes.
- Improve sustainability with greener processes.

SHARE YOUR REQUIREMENT [CLICK HERE](#)

📍 19/A, Punit Industries, D-1 Block MIDC Chinchwad, Pune: 411019

☎ +91 8530390457 / +91 9765800457

✉ [info@synvisionchem.com](mailto:info@synvisionchem.com)

🌐 <http://www.synvisionchem.com>